000120165 001__ 120165
000120165 005__ 20240319081010.0
000120165 0247_ $$2doi$$a10.1021/acsanm.2c03220
000120165 0248_ $$2sideral$$a131170
000120165 037__ $$aART-2022-131170
000120165 041__ $$aeng
000120165 100__ $$0(orcid)0000-0002-0970-1917$$aFernández-Afonso, Yilian
000120165 245__ $$aInfluence of magnetic nanoparticle degradation in the frame of magnetic hyperthermia and photothermal treatments
000120165 260__ $$c2022
000120165 5060_ $$aAccess copy available to the general public$$fUnrestricted
000120165 5203_ $$aThis work aims at studying how the transformations that magnetic nanoparticles suffer in vivo affect their heating properties in the frame of hyperthermia treatments. Iron oxide magnetic nanoparticles (≈13 nm) with two different coatings [PMAO (polymaleic anhydride-alt-1-octadecene) and DMSA (dimercaptosuccinic acid)] have been subjected to an accelerated degradation in a medium simulating lysosome conditions. The particles physicochemical properties (size, size distribution, and magnetic properties) have been followed over the degradation process along 24 days. It was found that DMSA-coated particles degraded much faster than PMAO-coated ones. In addition, their heating properties under both the exposure to an alternating magnetic field or a near infrared light have been tracked along this degradation processes, assessing how the changes in their physicochemical properties affect their heating capacity. Along the degradation procedure, a stronger decrease of the particles heating properties has been observed in the frame of magnetic hyperthermia measurements, in comparison with the photothermal ones. Finally, the PMAO-coated particles have been selected for a degradation study in vivo after intratumoral administration. Interestingly, although the number of particles decreases with time in the tissue, the size and size distribution of the particles do not change significantly over time. This work is especially relevant in the frame of the design of in vivo hyperthermia treatments using magnetic nanoparticles as it would provide fundamental clues regarding the need of repeated doses or the possible use of a single administration depending on the treatment duration.
000120165 536__ $$9info:eu-repo/grantAgreement/ES/DGA-FEDER/E15-17R$$9info:eu-repo/grantAgreement/ES/MICINN/PGC2018-096016-B-I00$$9info:eu-repo/grantAgreement/ES/MINECO/RYC-2015-17640
000120165 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000120165 590__ $$a5.9$$b2022
000120165 592__ $$a1.193$$b2022
000120165 591__ $$aNANOSCIENCE & NANOTECHNOLOGY$$b44 / 107 = 0.411$$c2022$$dQ2$$eT2
000120165 593__ $$aMaterials Science (miscellaneous)$$c2022$$dQ1
000120165 591__ $$aMATERIALS SCIENCE, MULTIDISCIPLINARY$$b98 / 343 = 0.286$$c2022$$dQ2$$eT1
000120165 594__ $$a7.9$$b2022
000120165 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000120165 700__ $$aAsín, Laura
000120165 700__ $$0(orcid)0000-0003-4516-8694$$aBeola, Lilianne
000120165 700__ $$0(orcid)0000-0001-5559-8757$$aFratila, Raluca M.
000120165 700__ $$0(orcid)0000-0003-2366-3598$$aGutiérrez, Lucía$$uUniversidad de Zaragoza
000120165 7102_ $$12009$$2750$$aUniversidad de Zaragoza$$bDpto. Química Analítica$$cÁrea Química Analítica
000120165 773__ $$g5, 11 (2022), 16220-16230$$pACS appl. nano mater.$$tACS APPLIED NANO MATERIALS$$x2574-0970
000120165 8564_ $$s4992555$$uhttps://zaguan.unizar.es/record/120165/files/texto_completo.pdf$$yVersión publicada
000120165 8564_ $$s3294196$$uhttps://zaguan.unizar.es/record/120165/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000120165 909CO $$ooai:zaguan.unizar.es:120165$$particulos$$pdriver
000120165 951__ $$a2024-03-18-15:01:49
000120165 980__ $$aARTICLE